Kalamazoo, Mich. — May 21, 2026 — Stryker Corporation, a global leader in medical technologies, has officially announced a significant transition within its executive finance leadership team. William Berry Jr., who has served as the company’s Chief Accounting Officer (CAO) since 2021, is set to retire this coming September, marking the conclusion of a distinguished tenure at the medical device giant. Emily Baculik, the company’s current Corporate Controller, has been tapped to succeed him, signaling a strategic continuity in the firm’s financial oversight.
This transition occurs at a pivotal time for Stryker, as the organization continues to navigate an increasingly complex global regulatory landscape and pursues aggressive growth targets in the medtech sector.
Main Facts: The Changing of the Guard
The announcement, formalized on May 21, 2026, confirms that William Berry Jr. will step down from his post after years of navigating Stryker through critical financial reporting cycles. Berry’s departure is part of a planned succession strategy, ensuring that the company maintains its high standards for fiscal transparency and operational efficiency.
Emily Baculik, who has served as Stryker’s Corporate Controller since November 2024, will assume the mantle of Chief Accounting Officer immediately following Berry’s retirement. Baculik’s promotion is widely viewed by industry analysts as a natural progression, given her deep integration into the company’s financial framework over the past several years. Her appointment underscores Stryker’s internal commitment to cultivating leadership talent from within the organization, fostering a culture of long-term strategic alignment.
Chronology: A Path to Leadership
To understand the weight of this transition, one must look at the career trajectories of both the outgoing and incoming executives.
William Berry Jr.’s Tenure
Berry joined the ranks of Stryker’s leadership during a period of robust expansion. His appointment as Chief Accounting Officer in 2021 was preceded by his successful stint as the company’s Corporate Controller. During his tenure as CAO, Berry was instrumental in overseeing the company’s financial reporting infrastructure, ensuring compliance with evolving SEC requirements, and managing the complexities of global taxation as Stryker expanded its footprint in orthopedics, med-surg, and neurotechnology.
Emily Baculik’s Ascent
Baculik’s path to the C-suite is characterized by a steady climb through the financial hierarchy of large-cap industrial and technology firms. Her tenure at Stryker began well before her promotion to Corporate Controller in late 2024. Prior to that role, she served as the Vice President of Finance for Stryker’s Spine Division—a role that required a deep understanding of product-line profitability and the specific economic drivers of the medical device market. Even before her leadership within the Spine division, she held the position of Senior Director of Finance, where she honed her skills in corporate governance and capital allocation.
Supporting Data: Financial Expertise and Compensation
The appointment of Baculik is not merely a change in title; it is a recalibration of the company’s financial leadership team. With over two decades of experience in the finance and accounting sectors, Baculik brings a wealth of institutional knowledge from her time at several high-profile, publicly traded companies, including Eaton, Rockwell Collins, and U.S. Steel. This diverse background provides her with a macro-economic perspective that is vital for a company with the scale and global reach of Stryker.
Compensation Structure
In her new role as Chief Accounting Officer, Baculik will see a shift in her compensation package, reflecting the increased scope of her responsibilities. According to the company’s disclosure:
- Base Salary: Her base salary will be set at $420,000 per annum.
- Incentive Bonus: She will be eligible for an annual incentive bonus target of 45% of her base salary. This bonus will be prorated based on her official start date as CAO in 2026.
- Long-Term Incentives: Stryker has committed to recommending that its board of directors approve additional awards under the company’s long-term incentive plan (LTIP). This move is designed to align her interests with the long-term appreciation of Stryker’s stock and the sustained financial health of the organization.
Implications: Strategic Continuity and Market Outlook
The transition from Berry to Baculik represents a commitment to stability. In the volatile environment of the medical technology industry, where mergers, acquisitions, and R&D expenditures are constant, the role of the Chief Accounting Officer is paramount.
Maintaining Financial Rigor
As Stryker continues to integrate new technologies into its portfolio, the internal controls and accounting precision managed by the CAO become the bedrock upon which the company’s investor relations are built. Baculik’s familiarity with Stryker’s internal systems—having served as both the VP of Finance for the Spine division and the Corporate Controller—ensures that there will be minimal disruption to the company’s financial reporting cycles.
Leadership Pipeline
Industry analysts often look for a robust "bench" when evaluating the health of an organization’s management team. By promoting from within, Stryker reinforces its reputation as a company that develops its own leaders. This strategy reduces the risks typically associated with executive onboarding, such as a lack of cultural fit or a misalignment with the company’s specific business model.
Future Challenges
Looking ahead, the new CAO will face a unique set of challenges. These include:
- Inflationary Pressures: Managing the impact of raw material costs and labor inflation on the cost of goods sold (COGS).
- Global Compliance: Keeping pace with the changing regulatory environments in both the European Union (EU MDR) and the United States, which impact how financial data is captured and reported regarding product life cycles.
- Digital Transformation: As Stryker incorporates more AI and robotic-assisted technology into its products, the accounting treatments for these long-term investments will require sophisticated oversight.
Official Responses and Corporate Sentiment
While Stryker has not yet issued a broad, multi-page press release focusing on the emotional sentiment of the departure, the filing clearly emphasizes the board’s confidence in the succession plan. The transition is presented as a "planned and orderly" process.
The internal sentiment, according to sources familiar with the company’s culture, is one of respect for Berry’s legacy and anticipation for Baculik’s leadership. Berry’s retirement is viewed as a natural conclusion to a successful career, while Baculik is regarded as a high-performing executive who has proven her mettle in both divisional and corporate-level finance.
Conclusion
The retirement of William Berry Jr. marks the end of an era for Stryker’s finance department, yet the company’s swift move to install Emily Baculik as his successor suggests a well-oiled machine. By leveraging her extensive experience at firms like Eaton and Rockwell Collins, combined with her intimate knowledge of Stryker’s operations, Baculik is well-positioned to uphold the company’s commitment to financial excellence.
As Stryker enters the latter half of 2026, the company appears focused on maintaining its momentum. With a clear succession plan and a seasoned financial leader stepping into the role, the organization remains well-prepared to face the fiscal demands of the evolving global medtech landscape. The transition will be officially finalized in September, at which point Baculik will take full responsibility for the company’s accounting functions, reporting directly to the leadership team and the board of directors.
As stakeholders observe this transition, the overarching narrative is one of stability. In the world of high-stakes medical technology, where every dollar must be accounted for to ensure the development of life-saving products, the appointment of a leader with such deep operational experience is a positive indicator for Stryker’s future stability and growth.
